Melinta Therapeutics has entered into a loan and securities financing agreement with Oberland Capital Management​. Proceeds from this financing will be used primarily to fund commercialization activities for Baxdela, which was recently approved by the FDA for the treatment of Acute Bacterial Skin and Skin Structure Infections.

“This largely non-dilutive financing gives us increased flexibility to fund our continuing commercialization efforts for Baxdela’s first approved indication, and to support indication-expanding studies in community-acquired bacterial pneumonia,” said Paul Estrem, Melinta’s chief financial officer.